مضادات الأندروجين الستيرويدية
مراجع

↑  Schröder، Fritz H.؛ Radlmaier، Albert (2009). "Steroidal Antiandrogens". في V. Craig Jordan؛ Barrington J. A. Furr (المحررون). Hormone Therapy in Breast and Prostate Cancer. Humana Press. ص. 325–346. DOI:10.1007/978-1-59259-152-7_15. ISBN:978-1-60761-471-5. مؤرشف من الأصل في 2021-11-04.
1 2  Singh SM، Gauthier S، Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr. Med. Chem. ج. 7 ع. 2: 211–47. DOI:10.2174/0929867003375371. PMID:10637363.
↑  Migliari R، Muscas G، Murru M، Verdacchi T، De Benedetto G، De Angelis M (1999). "Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy". Arch Ital Urol Androl. ج. 71 ع. 5: 293–302. PMID:10673793.
↑  Akakura، K.؛ Furuya، Y.؛ Ito، H. (أغسطس 1998). "[Steroidal and nonsteroidal antiandrogens: chemical structures, mechanisms of action and clinical applications]". Nihon Rinsho. Japanese Journal of Clinical Medicine. ج. 56 ع. 8: 2124–2128. ISSN:0047-1852. PMID:9750520.
↑  Erem C (2013). "Update on idiopathic hirsutism: diagnosis and treatment". Acta Clin Belg. ج. 68 ع. 4: 268–74. DOI:10.2143/ACB.3267. PMID:24455796.
↑  Reisner SL، Radix A، Deutsch MB (أغسطس 2016). "Integrated and Gender-Affirming Transgender Clinical Care and Research". J. Acquir. Immune Defic. Syndr. 72 Suppl 3: S235–42. DOI:10.1097/QAI.0000000000001088. PMC:4969060. PMID:27429189. There are many different androgen blockers used for transition care. Spironolactone, an aldosterone receptor antagonist, is frequently used in the United States, whereas cyproterone acetate, a synthetic steroidal antiandrogen with prostogenic properties, is predominantly outside of the United States.
↑  Gooren LJ (2011). "Clinical practice. Care of transsexual persons". N. Engl. J. Med. ج. 364 ع. 13: 1251–7. DOI:10.1056/NEJMcp1008161. PMID:21449788. ... Hormone therapy is prescribed for male-to-female transsexuals to induce breast formation and ... To achieve these goals, the biologic action of androgens must be almost completely neutralized. ... combining this treatment [of administrating estrogens] with ... other medications that suppress androgen action (e.g., سيبروتيرون أسيتات, ...) appears to be more effective. ...
↑  Wein AJ، Kavoussi LR، Novick AC، Partin AW، Peters CA (25 أغسطس 2011). Campbell-Walsh Urology: Expert Consult Premium Edition: Enhanced Online Features and Print, 4-Volume Set. Elsevier Health Sciences. ص. 2938–. ISBN:978-1-4160-6911-9. مؤرشف من الأصل في 2018-06-19.
↑  Kjeld JM، Puah CM، Kaufman B، Loizou S، Vlotides J، Gwee HM، Kahn F، Sood R، Joplin GF (1979). "Effects of norgestrel and ethinyloestradiol ingestion on serum levels of sex hormones and gonadotrophins in men". Clinical Endocrinology. ج. 11 ع. 5: 497–504. DOI:10.1111/j.1365-2265.1979.tb03102.x. PMID:519881.
↑  Miyamoto H، Messing EM، Chang C (2004). "Androgen deprivation therapy for prostate cancer: current status and future prospects". The Prostate. ج. 61 ع. 4: 332–53. DOI:10.1002/pros.20115. PMID:15389811.
↑  Jack H. Mydlo؛ Ciril J. Godec (11 يوليو 2003). Prostate Cancer: Science and Clinical Practice. Academic Press. ص. 437–. ISBN:978-0-08-049789-1. مؤرشف من الأصل في 2020-12-19.
↑  William D. Figg؛ Cindy H. Chau؛ Eric J. Small (14 سبتمبر 2010). Drug Management of Prostate Cancer. Springer Science & Business Media. ص. 99–. ISBN:978-1-60327-829-4. مؤرشف من الأصل في 2020-12-19.
بوابة الكيمياء
بوابة صيدلة
بوابة طب